Stryker Corporation $SYK Stock Holdings Lifted by Woodley Farra Manion Portfolio Management Inc.

Woodley Farra Manion Portfolio Management Inc. grew its stake in shares of Stryker Corporation (NYSE:SYK) by 1.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 146,712 shares of the medical technology company’s stock after acquiring an additional 2,536 shares during the quarter. Stryker makes up about 2.7% of Woodley Farra Manion Portfolio Management Inc.’s portfolio, making the stock its 17th biggest position. Woodley Farra Manion Portfolio Management Inc.’s holdings in Stryker were worth $58,166,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Mid American Wealth Advisory Group Inc. purchased a new stake in Stryker during the second quarter valued at about $26,000. Sachetta LLC lifted its position in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares in the last quarter. Ridgewood Investments LLC boosted its stake in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares during the period. Ransom Advisory Ltd purchased a new position in Stryker during the 1st quarter worth approximately $37,000. Finally, Solstein Capital LLC acquired a new stake in Stryker during the 2nd quarter valued at $43,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on SYK shares. BTIG Research reissued a “buy” rating and set a $410.00 price target on shares of Stryker in a research report on Friday. Truist Financial increased their price target on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research report on Friday. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Barclays increased their target price on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Redburn Partners set a $420.00 price target on shares of Stryker in a report on Thursday, September 18th. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Insider Transactions at Stryker

In related news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 520,500 shares of company stock worth $184,803,065. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

NYSE SYK opened at $362.39 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $138.59 billion, a PE ratio of 48.00, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a 50 day moving average price of $371.96 and a two-hundred day moving average price of $381.15.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.